Paul A. Stone - Aug 16, 2023 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Signature
/s/ Jason Throne, as Attorney-in-Fact for Paul A. Stone
Stock symbol
IDYA
Transactions as of
Aug 16, 2023
Transactions value $
-$106,105
Form type
4
Date filed
8/18/2023, 06:33 PM
Previous filing
Aug 11, 2023
Next filing
Aug 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Sale -$2.65K -100 -0.52% $26.45 19.2K Aug 16, 2023 Direct F1
transaction IDYA Common Stock Sale -$2.64K -100 -0.52% $26.40 19.1K Aug 16, 2023 Direct F1
transaction IDYA Common Stock Sale -$101K -3.82K -20.01% $26.38 15.3K Aug 18, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $26.37 to $26.415, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.